Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development and application of endomicroscopic imaging technologies for medical, translational and pre-clinical markets. We have a strong purpose of transforming people’s lives through the earlier and less invasive diagnosis and treatment of cancer and are on a journey to achieve this globally. We strive to give healthcare providers and researchers the highest quality in-vivo microscopic imaging tools to enable the early detection and management of disease, in order to improve patient outcomes and reduce the high cost of curative medicine. Our technology, used by leading research institutions and hospitals in North America, Europe, Asia and Australia enables real-time, in vivo imaging at the cellular level in human and animal tissue.
Our technology is at the heart of the Carl Zeiss Meditec CONVIVO device used successfully in neurosurgery. In collaboration with Pentax Medical, we released the first-ever human confocal endomicroscope for gastroenterology. Our FIVE2 ViewnVivo system builds upon our previously successful FIVE1 platform with enhanced 3D imaging features enabling virtual biopsies of live tissue. New applications in the identification of dysplastic and diseased tissue, tumour margins, molecular disease markers, women’s health, veterinary and research applications are being developed in association with world-leading institutions.
Company’s Keywords:
microscopic imaging technologies
<20
<232000
<1994